| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11471400 | HIKMA | Phenylephrine hydrochloride ready-to-use solution |
Aug, 2036
(12 years from now) | |
| US11213480 | HIKMA | Phenylephrine hydrochloride ready-to-use solution |
Sep, 2036
(12 years from now) | |
Immphentiv is owned by Hikma.
Immphentiv contains Phenylephrine Hydrochloride.
Immphentiv has a total of 2 drug patents out of which 0 drug patents have expired.
Immphentiv was authorised for market use on 09 March, 2023.
Immphentiv is available in solution;intravenous dosage forms.
The generics of Immphentiv are possible to be released after 26 September, 2036.
Drugs and Companies using PHENYLEPHRINE HYDROCHLORIDE ingredient
Market Authorisation Date: 09 March, 2023
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
IMMPHENTIV family patents
